NanoVibronix, Inc. (NAOV)
NanoVibronix, Inc. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Elmsford, NY, US. The stock last traded at $1.90, up 1.06% on the session, giving a market capitalisation of $1.5M. On trailing twelve-month figures it carries a trailing P/E of -0.07, a net margin of -894.6%. Its beta of 2.06 implies it has historically moved more than the broad market.
NanoVibronix, Inc., operating through its subsidiary NanoVibronix Ltd., develops and commercializes innovative, non-invasive devices that stimulate biological responses for therapeutic purposes. Their core focus areas include mitigating biofilm formation, accelerating wound repair, and alleviating pain. Key among their product line is UroShield, an ultrasound-based solution engineered to deter bacterial colonization and biofilm development in urinary catheters, thereby boosting antibiotic efficacy and reducing associated patient discomfort. They also offer PainShield and WoundShield, both patch-based therapeutic ultrasound technologies. PainShield targets relief from pain, muscle spasms, and joint contractures, while WoundShield is designed to foster tissue regeneration and promote healing in wounds. The company distributes these products directly to consumers and via extensive distributor networks spanning the United States, Israel, Europe, India, and numerous other international regions. Founded in 2003, NanoVibronix, Inc. maintains its corporate headquarters in Elmsford, New York.
NanoVibronix, Inc. is most often compared with the following Healthcare names: